Leuven Belgium, 03 September 2024: reMYND NV, a biotech company active in the field of neurodegeneration, is pleased to announce changes to its management team and Board of Directors, with the appointment of Floor Stam as CEO and Johan Cardoen as Chairman.
Floor Stam is a biotech entrepreneur and executive with significant experience developing early-stage companies. Floor co-founded oncology company Flamingo Therapeutics N.V. and held various roles in its leadership team, bringing the company to Phase 2 clinical stage within four years. Floor is a neurobiologist by training with a PhD from Vrije Universiteit Amsterdam, postdoctoral training at the Salk Institute for Biological Studies, and continued her career commercializing various technologies developed at VIB in Belgium before starting Flamingo. She takes up the role of CEO of reMYND as of September 2024.
Johan Cardoen, a seasoned biotech executive, has been appointed Chairman of reMYND’s Board. In the past he has served and continues to serve on the boards of a number of biotech companies. Until April 2020, Johan was Managing Director of VIB, where he oversaw VIB’s Innovation and Business Team. He was previously CEO of CropDesign N.V., overseeing its acquisition by BASF Plant Science in 2006.
Floor Stam, CEO of reMYND, said: “reMYND’s work in the field of neurodegeneration is very exciting. We now know that targeting the septin cytoskeleton leads to symptomatic relief in patients and holds the potential to slow down disease progression at the same time. The mechanism is novel and was recently published in Science. I am convinced that this program can be a true game-changer in the field. Together with the reMYND team, Johan and the Board, we will advance our lead asset as well as the earlier programs for the benefit of patients and caregivers and towards a value inflection for the company.”
Johan Cardoen, Chairman of the Board, said: “I am impressed with the recent progress made on the AD program and look forward to work with Floor and the Board to bring the company to the next level.”
About reMYND
reMYND is a company developing innovative treatments for neurodegenerative diseases caused by neuronal dysfunction. Its proprietary drug discovery platform enables the identification of novel mechanisms-of-action, innovative targets and first-in-class small molecules.
reMYND’s small molecule program of septin modulators (Science; PMID: 38815015) is the most advanced program with PoC demonstrated in AD patients using a first-generation compound. Currently a highly optimized septin modulator is in IND-enabling studies. reMYND’s Huntington program is 12 months pre-IND.
reMYND wis a spin-off from the University of Leuven, and has been substantially supported by grants from VLAIO/IWT (Flanders, Belgium). Find out more at https://www.remynd.com; Ph: +32 (0)16 751420; e-mail: remynd@remynd.com.